Ffcm LLC acquired a new position in Sarepta Therapeutics Inc (NASDAQ:SRPT) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,000 shares of the biotechnology company’s stock, valued at approximately $162,000.
A number of other large investors have also recently added to or reduced their stakes in SRPT. FMR LLC lifted its holdings in shares of Sarepta Therapeutics by 0.9% in the 2nd quarter. FMR LLC now owns 9,749,879 shares of the biotechnology company’s stock worth $1,288,739,000 after buying an additional 82,453 shares during the period. BlackRock Inc. lifted its holdings in shares of Sarepta Therapeutics by 2.6% in the 3rd quarter. BlackRock Inc. now owns 4,808,259 shares of the biotechnology company’s stock worth $776,581,000 after buying an additional 121,003 shares during the period. Jennison Associates LLC lifted its holdings in shares of Sarepta Therapeutics by 0.5% in the 3rd quarter. Jennison Associates LLC now owns 1,219,503 shares of the biotechnology company’s stock worth $196,962,000 after buying an additional 5,604 shares during the period. Eagle Asset Management Inc. lifted its holdings in shares of Sarepta Therapeutics by 55.1% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,067,318 shares of the biotechnology company’s stock worth $172,382,000 after buying an additional 379,162 shares during the period. Finally, RTW Investments LP lifted its holdings in shares of Sarepta Therapeutics by 42.2% in the 2nd quarter. RTW Investments LP now owns 978,551 shares of the biotechnology company’s stock worth $129,345,000 after buying an additional 290,280 shares during the period. 92.04% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:SRPT opened at $119.35 on Monday. Sarepta Therapeutics Inc has a 1 year low of $50.68 and a 1 year high of $176.50. The stock has a market cap of $7.98 billion, a P/E ratio of -72.77 and a beta of 1.59. The company has a current ratio of 8.85, a quick ratio of 7.84 and a debt-to-equity ratio of 0.65.
Several brokerages have weighed in on SRPT. Zacks Investment Research cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 21st. BidaskClub cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 15th. Citigroup upped their target price on Sarepta Therapeutics from $174.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, November 6th. Piper Jaffray Companies reduced their price target on Sarepta Therapeutics from $189.00 to $168.00 and set an “overweight” rating for the company in a research report on Friday, October 26th. Finally, Sanford C. Bernstein began coverage on Sarepta Therapeutics in a research report on Friday, October 12th. They issued an “outperform” rating and a $170.00 price target for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-three have issued a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $169.19.
In other news, CEO Douglas S. Ingram acquired 16,695 shares of the business’s stock in a transaction dated Tuesday, October 30th. The shares were acquired at an average cost of $120.39 per share, with a total value of $2,009,911.05. Following the completion of the acquisition, the chief executive officer now owns 412,811 shares of the company’s stock, valued at $49,698,316.29. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Sandesh Mahatme sold 107,524 shares of the stock in a transaction dated Wednesday, October 24th. The shares were sold at an average price of $127.74, for a total value of $13,735,115.76. Following the completion of the transaction, the chief financial officer now directly owns 48,381 shares in the company, valued at $6,180,188.94. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.
WARNING: This news story was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.wkrb13.com/2018/11/26/1000-shares-in-sarepta-therapeutics-inc-srpt-purchased-by-ffcm-llc.html.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Featured Story: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.